Camrelizumab In Advanced Or Metastatic Solid Tumor Patients With Microsatellite Instability-High/Mismatch Repair-Deficient: Results From An Open-Label Exploratory Study.
JOURNAL OF CLINICAL ONCOLOGY（2020）
Abstract
e15140Background: PD-1 checkpoint inhibitor has been shown a significant effect in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumor. Herei...
MoreTranslated text
Key words
microsatellite instability–high/mismatch,camrelizumab,metastatic solid tumor patients,repair-deficient,open-label
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined